RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

<strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, desi...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Healer, J, Thompson, JK, Mackwell, KL, Browne, CD, Seager, BA, Ngo, A, Lowes, KN, Silk, SE, Pulido, D, King, LDW, Christen, JM, Noe, AR, Kotraiah, V, Masendycz, PJ, Rajagopalan, R, Lucas, L, Stanford, MM, Soisson, L, Diggs, C, Miller, R, Youll, S, Wycherley, K, Draper, SJ, Cowman, AF
Natura:	Journal article
Lingua:	English
Pubblicazione:	Frontiers Media 2022

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

Documenti analoghi